Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Givastomig |
Synonyms | |
Therapy Description |
TJ033721 is a bispecific antibody that targets claudin 18.2 (CLDN18.2) and TNFRSF9 (4-1BB), which potentially results in activation of immune cells and antitumor activity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Givastomig | ABL111|TJ-CD4B|CLDN18.2 x 4-1BB BsAb TJ-CD4B|TJ033721 | CLDN18.2 Antibody 19 | Givastomig is a bispecific antibody that targets claudin 18.2 (CLDN18.2) and TNFRSF9 (4-1BB), which potentially results in activation of immune cells and antitumor activity (Ann Oncol (2024) 35 (suppl_2): S689, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04900818 | Phase I | Givastomig | Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |